To the full analysis
Buyback calculator for Heidelberg Pharma
Heidelberg Pharma stock: key metrics
HPHA.DEHeidelberg Pharma had an operating margin of −3,255.4% and a return on invested capital (ROIC) of −93.9% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | no data | no data | no data |
| 2007 | no data | no data | no data |
| 2008 | no data | no data | no data |
| 2009 | 100.0% | −128.6% | −127.3% |
| 2010 | no data | no data | no data |
| 2011 | 57.8% | −135.5% | −141.0% |
| 2012 | 62.2% | −49.9% | −52.6% |
| 2013 | 72.4% | −37.3% | −37.8% |
| 2014 | 62.3% | −155.0% | −158.5% |
| 2015 | 50.1% | −285.3% | −286.8% |
| 2016 | 40.6% | −467.0% | −469.1% |
| 2017 | 49.6% | −565.9% | −577.4% |
| 2018 | 39.8% | −318.2% | −318.2% |
| 2019 | 48.8% | −141.8% | −138.8% |
| 2020 | 34.0% | −218.7% | −216.5% |
| 2021 | −62.4% | −866.1% | −900.6% |
| 2022 | 74.7% | −92.8% | −106.4% |
| 2023 | 67.0% | −215.1% | −206.4% |
| 2024 | 74.0% | −301.7% | −283.0% |
| 2025 | −81.4% | −3,255.4% | −2,901.1% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 0.0% | −24.1% | 0.0% |
| 2007 | 0.0% | −38.8% | 0.0% |
| 2008 | −100.0% | −77.4% | −100.0% |
| 2009 | −100.0% | no data | −100.0% |
| 2010 | 200.0% | no data | −100.0% |
| 2011 | 200.0% | no data | −66.9% |
| 2012 | −47.1% | −40.5% | −24.9% |
| 2013 | −33.7% | −94.3% | −22.6% |
| 2014 | −48.0% | −47.5% | −37.9% |
| 2015 | −69.1% | −57.4% | −54.1% |
| 2016 | −65.5% | −58.8% | −41.9% |
| 2017 | −29.6% | −33.6% | −26.4% |
| 2018 | −45.1% | −29.3% | −37.4% |
| 2019 | −62.3% | −38.6% | −44.1% |
| 2020 | −100.0% | −99.4% | −93.7% |
| 2021 | −100.0% | no data | −100.0% |
| 2022 | −29.6% | −25.7% | −19.6% |
| 2023 | −41.2% | −23.2% | −28.9% |
| 2024 | −62.8% | −92.9% | −31.9% |
| 2025 | 200.0% | −93.9% | −100.0% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 30 Nov 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = €0.9024)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Weak, published since 7 Nov 2026 (in the score history since 31 Mar 2021)
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.